Received grant in 2018
25-40 percent of patients with colorectal cancer are having relapses despite therapeutic treatment.
A few smaller studies have found that acetylsalicylic acid (ASA) treatment is extending the survival of patients with colorectal cancer, if their tumor had mutations in the PIK3 signaling pathway. The PIK3 signaling pathway is important for both growth and survival of cells.
The purpose of ALASCCA is, by lottery, to examine if ASA treatment can lower the risk of relapse and thereby improve the survival rate for patients having undergone surgery for colorectal cancer.
Project stakeholders
- Lene Hjerrild Iversen, Department of Surgery P, Aarhus University Hospital. Primary contact, mail: leneiver@rm.dk
- Katrine Emmertsen, Speciality Registrar and Head of Research, Department of Gastrointestinal, Randers Regional Hospital (preparation of ALASCCA trial just launched)
- Uffe Schou Løve, Consultant, Department of Gastrointestinal and Breast Surgery, Viborg Regional Hospital
- Tue Avlund, Department of Surgery, Horsens Regional Hospital
- Christina Tinghus, Head Consultant, Department of Surgery, Sydvestjysk Sygehus (Esbjerg)
- Ismail Gögenur, Professor, Department of Surgery, Zealand University Hospital (Roskilde)